BAFNA PHARMACEUTICALS LTD Intrinsic Value
BAFNAPH · Healthcare · Current price ₹225.88
Is BAFNA PHARMACEUTICALS LTD undervalued?
DocStoX estimates the fair value of BAFNA PHARMACEUTICALS LTD at ₹43 per share, versus the current market price of ₹226. That puts the stock about -80.8% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹32), Relative P/E (₹68), Graham floor (₹40). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹32 (bear) to ₹43 (base) to ₹68 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Margin of safety
Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹226 versus an intrinsic value of ₹43, BAFNA PHARMACEUTICALS LTD currently offers -80.8% of negative margin (i.e. a premium).
More on BAFNA PHARMACEUTICALS LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.